EDISON EQUITY RESEARCH - HALOZYME THERAPEUTICS
13 April 2015 - 11:10PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH: HALOZYME THERAPEUTICS - HOPE
IN PANCREATIC CANCER
Halozyme hosted an analyst day in January, which focused on its
PEGPH20 programme in pancreatic and non-small cell lung cancer
(NSCLC). It presented interim data from Stage 1 of a Phase II trial
where PEGPH20 in combination with the standard of care demonstrated
a 71% response rate, compared to just 29% for the standard of care
alone. Also, progression-free survival more than doubled in the
treatment arm. We have increased our valuation to $15.31 per share
from $11.70 per share.
Halozyme Therapeutics focuses on the development of extracellular
matrix-based drugs. Its rHuPH20-based delivery platform has been
used by partners, including Roche, Baxter and Pfizer, to develop SC
injection of IV drugs such as Herceptin, Rituxan (Roche) and
GAMMAGARD (Baxter). Its pipeline consists of Hylenex, approved for
hydration and PEGPH20 in Phase II trials for pancreatic cancer.
To view our full report, please click here
Click here to view all of Edison Investment
Research’s published reports
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Jan 2025 to Feb 2025
Halozyme Therapeutics (NASDAQ:HALO)
Historical Stock Chart
From Feb 2024 to Feb 2025